NLS Pharmaceutics Ltd. (NASDAQ:NCEL – Get Free Report)’s share price was up 2.2% during trading on Wednesday . The company traded as high as $3.31 and last traded at $3.25. Approximately 4,901 shares changed hands during mid-day trading, a decline of 93% from the average daily volume of 67,647 shares. The stock had previously closed at $3.18.
NLS Pharmaceutics Stock Down 0.6%
The stock has a fifty day moving average price of $2.90 and a 200 day moving average price of $2.97.
Insiders Place Their Bets
In other NLS Pharmaceutics news, Director Olivier Samuel acquired 81,818 shares of the company’s stock in a transaction that occurred on Monday, April 27th. The stock was bought at an average price of $2.75 per share, for a total transaction of $224,999.50. Following the acquisition, the director directly owned 81,818 shares in the company, valued at $224,999.50. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Michel Revel acquired 54,545 shares of the company’s stock in a transaction that occurred on Monday, April 27th. The shares were acquired at an average price of $2.75 per share, with a total value of $149,998.75. Following the acquisition, the director owned 957,530 shares in the company, valued at $2,633,207.50. This trade represents a 6.04% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. 16.40% of the stock is owned by insiders.
About NLS Pharmaceutics
NLS Pharmaceutics (NASDAQ: NCEL) is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, with additional operations in the United States. The company focuses on the development of small-molecule therapies designed to address disorders of the circadian rhythm and sleep-wake cycle. It leverages proprietary controlled-release and receptor-targeting approaches to optimize drug exposure over a 24-hour period.
The core of NLS Pharmaceutics’ pipeline consists of novel melatonin receptor agonists aimed at treating rare and orphan sleep disorders such as non-24-hour sleep-wake disorder and idiopathic hypersomnia.
Read More
- Five stocks we like better than NLS Pharmaceutics
- SpaceX IPO: Opportunity? Or the Ultimate Hype Trade?
- CAVA Group’s Stock Looks Delicious After Strong Earnings
- Lowe’s Finds Support at $215 After Q1 Earnings Sell-Off
- Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook
Receive News & Ratings for NLS Pharmaceutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NLS Pharmaceutics and related companies with MarketBeat.com's FREE daily email newsletter.
